Estrogen effects on serum interleukin-8 and interleukin-10 expression in ovariectomized rats with osteoporosis

doi:10.3969/j.issn.2095-4344.2013.24.004

Abstract

Abstract:

BACKGROUND: The prevalence of osteoporosis is high in postmenopausal women, and whether estrogen prevents and treats osteoporosis through regulation of cytokine expression remains unclear.
OBJECTIVE: To observe the effect of estrogen on the expression levels of the cytokines, interleukin-8 and interleukin-10, and to explore the correction between bone mineral density and cytokines.
METHODS: Thirty healthy female Sprague-Dawley rats were included in this study and they were randomly divided into three groups: normal control group, model group and estradiol group. The rats of normal control group were subjected to laparotomy, while those of model group and estradiol group were completely ovariectomized. At 3 weeks after modeling, each rat of normal control group and model group was gavaged with 1.5 mL physiological saline every day, while the rats of estradiol group were given 1.5 mL estradiol valerate (1 mg/kg per day), for 12 weeks. The bone mineral density of femur and tibia was measured by dual-energy X-ray absorptiometry, and serum interleukin-8, interleukin-10 and estradiol levels were determined by enzyme linked immunosorbent assay.
RESULTS AND CONCLUSION: The serum expression levels of estradiol in the model group and estradiol group were significantly decreased compared with the normal control group (P < 0.05), indicating the success of ovariectomy. The serum interleukin-8 level was significantly higher in the model group than the normal control group and estradiol group (P < 0.01), but serum interleukin-10 levels were significantly higher in the latter two groups (P < 0.01). There was no significant difference in the interleukin-10 expression level between normal control group and estradiol group (P > 0.05). The bone mineral density of femur and tibia was significantly negatively correlated with serum interleukin-8 level (P < 0 .001), and significantly positively correlated with the serum interleukin-10 level (P < 0.05). Estrogen could down-regulate the expression level of interleukin-8, and up-regulate the expression level of interleukin-10. By regulating the cytokine expression levels, estradiol may be another mechanism of action for the prevention and treatment of osteoporosis in postmenopausal women.

Key words: tissue construction, bone tissue construction, ovariectomized rats, estradiol, estrogen, osteoporosis, animal model, femoral bone mineral density, tibial bone mineral density, interleukin-8, interleukin-10, cytokine, provincial grants-supported paper

CLC Number:

R318

Lu Shou-ming, Lu Shou-liang, Sun Tian-wei, Zhang Hang, Wang Qi-ming. Estrogen effects on serum interleukin-8 and interleukin-10 expression in ovariectomized rats with osteoporosis[J]. Chinese Journal of Tissue Engineering Research, 2013, 17(24): 4394-4400.

Figures/Tables 4

References

[1] Ding C, Parameswaran V, Udayan R,et al. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab. 2008;93(5):1952-1958.http://www.ncbi.nlm.nih.gov/pubmed/18285417

[2] Magaña JJ, Gómez R, Cisneros B,et al. Association of interleukin-6 gene polymorphisms with bone mineral density in Mexican women. Arch Med Res, 2008;39(6): 618-624.http://www.ncbi.nlm.nih.gov/pubmed/18662595

[3] Pino AM, Ríos S, Astudillo P,et al. Concentration of adipogenic and proinflammatory cytokines in the bone marrow supernatant fluid of osteoporotic women. J Bone Miner Res.2010;25(3):492-498.http://www.ncbi.nlm.nih.gov/pubmed/19653807

[4] Dieli-Conwright CM, Spektor TM, Rice JC,et al. Hormone therapy attenuates exercise-induced skeletal muscle damage in postmenopausal women. J Appl Physiol.2009;107(3): 853-858.http://www.ncbi.nlm.nih.gov/pubmed/19574506

[5] Wang Y, Li LZ, Zhang YL, et al. LC, a novel estrone-rhein hybrid compound, concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-κB ligand (RANKL) and interleukin-6 production by human osteoblastic cells. Mol Cell Endocrinol. 2011;337(1-2):43-51. http://www.ncbi.nlm.nih.gov/pubmed/21291955

[6] Iacovino JR．Mortality outcomes after osteoporotic fractures in men and women．J Insur Med. 2001;33(4):316-320.http://www.ncbi.nlm.nih.gov/pubmed/11877911

[7] Niu T,Rosen CJ.The insulin-like growth factor-I gene and osteoporosis:a critical appraisal. Gene. 2005;361:38-56．http://www.ncbi.nlm.nih.gov/pubmed/16183214

[8] Ali Gur, Aziz denli, Demzi Cexik, et al.The effects of Alendronate and calcitonin on cytokines in postmenopausal osteporosis:A 6-month randomized and controlled study.Yonsei Med J.2003;44(1): 99-109.http://www.ncbi.nlm.nih.gov/pubmed/12619182

[9] Williams LM, Sarma U, Willets K, et al. Expression of constitutively active STAT3 can replicate the cytokine suppressive activity of interleukin-10 in human primary macrophages. J Biol Chem.2007;282:6965-6975.http://www.ncbi.nlm.nih.gov/pubmed/17194701

[10] Zupan J, Komadina R, Marc J. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues. J Biomed Sci. 2012;19(1):28.http://www.ncbi.nlm.nih.gov/pubmed/22380539

[11] Inada M, Miyaura C. Cytokines in bone diseases. Cytokine and postmenopausal osteoporosis. Clin Calcium. 2010;20 (10):1467-1472.http://www.ncbi.nlm.nih.gov/pubmed/23055015

[12] Ralston SH. Analysis of gene expression in bone biopsies by polymerase chain reaction:evidence fern hanced eytokine expression in postmenopausal osteoporosis. J Bone Miner Res.1994;9:883-885.:http://www.ncbi.nlm.nih.gov/pubmed/8079663

[13] Gür A, Denli A, Cevik R,et al. The effects of alendronate and calcitonin on cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. Yonsei Med J. 2003; 44:99-109.http://www.ncbi.nlm.nih.gov/pubmed/12619182

[14] Liang JX, Chen G, Lin LX, et al. Zhonghua Guzhi Shusong he Gukuangyan Jibing Zazhi. 2011;4(1):32-35.梁继兴,陈刚,林丽香,等. 绝经前、后女性骨代谢指标与白介素-1β受体拮抗剂的关系[J]. 中华骨质疏松和骨矿盐疾病杂志, 2011, 4(1):32-35.http://d.wanfangdata.com.cn/Periodical_zhgzsshgkyjbzz201101005.aspx

[15] Li CG, Liu LH, Tang WD, et al. Zhongguo Laonianxue Zazhi. 2011;31(8):1320-1322.李彩格,刘丽华,唐蔚东,等. 血清瘦素和白介素-6水平与绝经期妇女骨代谢的关系[J]. 中国老年学杂志,2011,31(8):1320-1322.http://www.cnki.com.cn/Article/CJFDTotal-ZLXZ201108016.htm

[16] Sunyer T, Lewis J, Collin P, et al. Estrogen's bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells. J Clin Invest.1999;103(10): 1409-1418.http://www.ncbi.nlm.nih.gov/pubmed/10330423

[17] Ajay K Malik, Sophia Khaldoyanidi, Dominick L Auci, et al.5-Androstene-3β, 7β,17β-triol (β-AET) Slows Thermal Injury Induced Osteopenia in Mice: Relation to Aging and Osteoporosis.Plos One. 2010;5(10):e13566.http://www.ncbi.nlm.nih.gov/pubmed/21042414

[18] Cvoro A, Yuan C, Paruthiyil S, et al. Cross talk between glucocorticoid and estrogen receptors occurs at a subset of proinflammatory genes. J Immunol. 2011;186(7):4354-4360.http://www.ncbi.nlm.nih.gov/pubmed/21357268

[19] Lovibond AC, Haque SJ, Chambers TJ, et al. TGF-beta-induced SOCS3 expression augments TNF-alpha-induced osteoclast formation. Biochem Biophys Res Commun. 2003;309(4):762-767.http://www.ncbi.nlm.nih.gov/pubmed/13679037

[20] Hong MH, Williams H, Jin CH, et al. The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine-phosphorylated proteins. J Bone Miner Res. 2000; 15(5):911-918.http://www.ncbi.nlm.nih.gov/pubmed/10804021

[21] Owens JM, Gallagher AC, Chambers TJ. IL-10 modulates formation of osteoclasts in murine hemopoietic cultures. J Immunol. 1996;157(2):936-940.http://www.ncbi.nlm.nih.gov/pubmed/8752948

[22] Percegoni N, Ferreira AC, Rodrigues CF, et al. Profile of serum IL-1beta and IL-10 shortly after ovariectomy and estradiol replacement in rats. Horm Metab Res. 2009; 41(1):50-54.http://www.ncbi.nlm.nih.gov/pubmed/18841529

[23] Aggarwal R, Lu J, Kanji S, et al. Human umbilical cord blood-derived CD34+ cells reverse osteoporosis in NOD/SCID mice by altering osteoblastic and osteoclastic activities. PLoS One. 2012;7(6):e39365.http://www.ncbi.nlm.nih.gov/pubmed/22724005

[24] Gür A, Denli A, Nas K, et al. Possible pathogenetic role of new cytokines in postmenopausal osteoporosis and changes during calcitonin plus calcium therapy. Rheumatol Int. 2002; 22(5):194-198.http://www.ncbi.nlm.nih.gov/pubmed/12215865

[25] Chen HY, Chen WC, Hsu CM, et al. Tumor necrosis factor alpha, CYP 17, urokinase, and interleukin 10 gene polymorphisms in postmenopausal women: correlation to bone mineral density and susceptibility to osteoporosis. Eur J Obstet Gynecol Reprod Biol. 2005;122(1):73-78.http://www.ncbi.nlm.nih.gov/pubmed/15927351

[26] Fan L, Lin H. Zhongguo Guzhi Susong Zazhi. 2011;17(5): 435-439. 范璐,林华.不同生理时期雌激素对骨量的影响[J].中国骨质疏松杂志,2011,17(5):435-439.http://www.cnki.com.cn/Article/CJFDTotal-ZGZS201105019.htm

[27] Shao BY, Yu Y, Fu X, et al. Zhongguo Bingli Shengli Zazhi. 2013;29(3):515-520.邵秉一,于洋,付欣,等. 雌激素缺乏导致的骨质疏松发病过程中骨髓间充质干细胞FasL表达降低对CD4＋ T淋巴细胞凋亡的影响[J]. 中国病理生理杂志,2013,29(3):515-520.http://www.cqvip.com/QK/92208X/201303/45247598.html

[28] Song JJ, Luo ZJ, Liu J, et al. Zhongguo Gu yu Guanjie Zazhi. 2013;11(2):84-89.宋佳峻,罗卓荆,刘建, 等. 糖皮质激素与卵巢摘除后对大鼠骨量及骨代谢影响的对比研究[J]. 中国骨与关节杂志,2013, 11(2): 84-89.http://d.wanfangdata.com.cn/Periodical_zggzlzz201302008.aspx

[29] Luo CY, Wang L, Sun C, et al. Estrogen enhances the functions of CD4(+)CD25(+)Foxp3(+) regulatory T cells that suppress osteoclast differentiation and bone resorption in vitro. Cell Mol Immunol. 2011;8(1):50-58.http://www.ncbi.nlm.nih.gov/pubmed/21200384

[30] Reich MS,Jarvis JP,Silva MJ,et al.Genetic relationships between obesity and osteoporosis in LGXSM recombinant inbred mice.Genet Res.2008;90(4):433-434.http://www.ncbi.nlm.nih.gov/pubmed/19061533

[31] Liu D, Yao S, Wise GE. Effect of interleukin-10 on gene expression of osteoclastogenic regulatory molecules in the rat dental follicle. Eur J Oral Sci. 2006;114(1):42-49. http://www.ncbi.nlm.nih.gov/pubmed/16460340

[32] Zheng Q, Liang N. Zhongguo Laonianxue Zazhi. 2012;32(17): 3651-3653.郑青,梁宁. 老年性骨质疏松患者血清细胞因子水平与OPG/RANKL/RANK轴的相关性[J]. 中国老年学杂志,2012, 32(17): 3651-3653.http://www.cnki.com.cn/Article/CJFDTotal-ZLXZ201217016.htm

[33] Sun Y, Yang L, Lv ZP, et al. Zhonguo Bingli Shengli Zazhi. 2011;27(4):755-758.孙影,杨丽,吕辰鹏,等. 骨碎补总黄酮对去卵巢骨质疏松模型大鼠血清中瘦素、白细胞介素6、前列腺素E_2及骨组织中β_2-肾上腺素受体的影响[J]. 中国病理生理杂志,2011,27(4): 755-758.http://www.cnki.com.cn/Article/CJFDTotal-ZBLS201104034.htm

[34] Liu XH,Kinchenbaum A,Yao S,et al.Cross-talk between the interleu-kin-6 and prostaglandin E(2)signaling system results in enhancement ofosteoclastogenesis through effects on the osteoprotegerin/receptor activatorof nuclear factor-κB(RANK) ligand RANK system. Endocrinology. 2005;146(8):1991-1998. http://www.ncbi.nlm.nih.gov/pubmed/15618359

[35] Wang XL, Zhang Y, Yu WH. Linchuang Huicui. 2007;22(4): 286-287.王秀玲,张颖,于文浩. 糖骨康对糖尿病骨质疏松患者血清骨钙素、肿瘤坏死因子α、白细胞介素6含量的影响[J]. 临床荟萃, 2007,22(4):286-287.http://www.cnki.com.cn/Article/CJFDTotal-LCFC200704036.htm

[36] LI ZW, Zhang MF, Zhao FY. Zhongguo Guzhi Shusong Zazhi. 2005;11(4):418-422.李忠武,章明放,赵凤云. 白细胞介素-1、-6mRNA在去势大鼠骨组织中的表达及其意义[J]. 中国骨质疏松杂志,2005,11(4): 418-422.http://www.cnki.com.cn/Article/CJFDTotal-LCFC200704036.htm